- Details
- Thomas Hope joins Phillip Koo to discuss real-world challenges associated with patient selection, laboratory abnormalities, and workflow issues in treating patients with lutetium-177 PSMA in a high-volume care center. He also talks about the need to identify when to stop therapy and how to spread out doses effectively while minimizing toxicity. Additionally, Dr. Hope highlights the importance of p...
|
- Details
- Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on treatme...
|
- Details
- Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of Medical Imaging, Medicine and B...
|
- Details
- Oliver Sartor and Alicia Morgans delve into the complexities of implementing Lutetium-177 in clinical practices, especially amid recent supply chain issues. Dr. Sartor emphasizes the importance of multidisciplinary care and effective communication between medical oncologists and radiation oncologists for successful patient management. He outlines the licensure requirements and safety protocols nec...
|
- Details
- From the Tulane Cancer Center, Kendra Harris, a radiation oncologist explains the process of preparing for administering a dose of Pluvicto™ (177Lu-PSMA-617). Lutetium-177 received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associat...
|
- Details
- From the Tulane Cancer Center, Kendra Harris, Chair of Radiation Oncology explains the process of preparing for treatment of Pluvicto™ (177Lu-PSMA-617). Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate...
|
- Details
- From the Tulane Cancer Center, Kendra Harris Chair of Radiation Oncology demonstrates the process of administering a dose of Pluvicto™ (177Lu-PSMA-617). Phillip Koo meets with the patient in a brief post-dose administration discussion. Lutetium recently received FDA approval as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer...
|
- Details
- Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...
|
- Details
- Chair of Radiation Oncology at Tulane University Cancer Center, Kendra Harris joins Phillip Koo to discuss radiation safety in regards to the recent approval of Pluvicto™, the first targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: Kendra Harris, MD, MSc, Chair, Radiation Oncology, Associate Professor, Tulane Cancer Center, Tulane Unive...
|
- Details
- Phillip Koo and Charlotte Manogue, GU Program Manager at Tulane Cancer Center discuss aspects of transitioning from a clinical trial model into a sustainable treatment program for 177Lu-PSMA-617 for advanced prostate cancer at Tulane Cancer Center in New Orleans, Louisiana. Biographies: Charlotte Manogue, MPH, Senior Clinical Research Coordinator, Tulane Cancer Center, Tulane University School of...
|
